Interactive presentation

My Journey to a Lupus Diagnosis: Advice for People Who are Newly Diagnosed

We will hear from Resa as she shares her journey starting when symptoms began to her diagnosis of lupus, providing her perspectives and advice for others who may be experiencing a similar situation.
Interactive presentation

Hey Doc, What Do You Know About SLE? Hear a Patient’s Perspective

The diagnosis of systemic lupus erythematosus can be shocking and life-changing. We will hear from Resa, a 28-year-old woman, who shares her experiences overcoming the challenges associated with diagnosis and long-term management of her disease, highlighting the importance of a positive patient-clinician relationship.
Suggested Readings

Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.

Choi MY, et al. Ann Rheum Dis. 2022. [E-pub ahead of print.]

Association of a combination of healthy lifestyle behaviors with reduced risk of incident systemic lupus erythematosus.

Choi MY, et al. Arthritis Rheumatol. 2022;74(2):274-283.

Update οn the diagnosis and management of systemic lupus erythematosus.

Fanouriakis A, et al. Ann Rheum Dis. 2021;80(1):14-25.

Two-year, randomized, controlled trial of belimumab in lupus nephritis.

Furie R, et al. N Engl J Med. 2020;383(12):1117-1128.

Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries.

Izmirly PM, et al. Arthritis Rheumatol. 2021;73(6):991-996.

All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.

Moghaddam B, et al. Rheumatology. 2021;61(1):367-376.

Trial of anifrolumab in active systemic lupus erythematosus.

Morand EF, et al. N Engl J Med. 2020;382(3):211-221.

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Rovin BH, et al. Lancet. 2021;397(10289):2070-2080.

SLE mortality remains disproportionately high, despite improvements over the last decade.

Singh RR, Yen EY. Lupus. 2018;27(10):1577-1581.

Linked Resources

Classification Criteria

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, et al. Arthritis Rheumatol. 2019;71(9):1400-1412.

Disease Management Guidelines

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.

Fanouriakis A, et al. Ann Rheum Dis. 2019;78(6):736-745.

Patient Resources

American College of Rheumatology

Lupus Foundation of America

Lupus Research Alliance

Related activities
POC101 
0.25 CME/CE

Evaluating the Patient with SLE

Module 1

Faculty: Ashira D. Blazer, MD, MSCI; Karen H. Costenbader, MD, MPH
Release: 04/29/2022
Expiration: 04/29/2023
Begin Activity
POC101 
0.25 CME/CE

Targeted Treatment Options for SLE

Module 3

Faculty: Ashira D. Blazer, MD, MSCI; Karen H. Costenbader, MD, MPH
Release: 05/30/2022
Expiration: 05/30/2023
Begin Activity
POC101 
0.25 CME/CE

Real-World Strategies for Managing Moderate-to-Severe SLE

Module 2

Faculty: Ashira D. Blazer, MD, MSCI; Karen H. Costenbader, MD, MPH
Release: 05/16/2022
Expiration: 05/16/2023
Begin Activity